Syndax Pharmaceuticals 관리

관리 기준 확인 2/4

Syndax Pharmaceuticals CEO는 Michael Metzger, Feb2022 에 임명되었습니다 의 임기는 2.75 년입니다. 총 연간 보상은 $ 9.13M, 7.4% 로 구성됩니다. 7.4% 급여 및 92.6% 보너스(회사 주식 및 옵션 포함). 는 $ 843.97K 가치에 해당하는 회사 주식의 0.062% 직접 소유합니다. 843.97K. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 8.3 년입니다.

주요 정보

Michael Metzger

최고 경영자

US$9.1m

총 보상

CEO 급여 비율	7.4%
CEO 임기	2.8yrs
CEO 소유권	0.06%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	8.3yrs

최근 관리 업데이트

Recent updates

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Oct 14

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Sep 20

Syndax: Gearing Up For Launches

Jun 21

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Jun 20

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Mar 28

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Mar 04

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Nov 20

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Sep 27

Syndax Pharmaceuticals Q2 2022 Earnings Preview

Aug 07

Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs

Apr 08

CEO 보상 분석

Michael Metzger 의 보수는 Syndax Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$297m
Jun 30 2024	n/a	n/a	-US$264m
Mar 31 2024	n/a	n/a	-US$241m
Dec 31 2023	US$9m	US$678k	-US$209m
Sep 30 2023	n/a	n/a	-US$176m
Jun 30 2023	n/a	n/a	-US$160m
Mar 31 2023	n/a	n/a	-US$153m
Dec 31 2022	US$4m	US$640k	-US$149m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	US$818k
Mar 31 2022	n/a	n/a	US$15m
Dec 31 2021	US$3m	US$594k	US$25m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$91m
Mar 31 2021	n/a	n/a	-US$86m
Dec 31 2020	US$2m	US$577k	-US$77m
Sep 30 2020	n/a	n/a	-US$71m
Jun 30 2020	n/a	n/a	-US$63m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$3m	US$540k	-US$56m
Sep 30 2019	n/a	n/a	-US$61m
Jun 30 2019	n/a	n/a	-US$65m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$2m	US$506k	-US$74m
Sep 30 2018	n/a	n/a	-US$74m
Jun 30 2018	n/a	n/a	-US$72m
Mar 31 2018	n/a	n/a	-US$67m
Dec 31 2017	US$1m	US$492k	-US$61m

보상 대 시장: Michael 의 총 보상 ($USD 9.13M )은 US 시장( $USD 5.37M ).

보상과 수익: 회사가 수익성이 없는 동안 Michael 의 보상이 증가했습니다.

CEO

Michael Metzger (53 yo)

2.8yrs

테뉴어

US$9,127,419

보상

Mr. Michael A. Metzger is a Director at Pyxis Oncology, Inc since June 10, 2024. Mr. Metzger has experience in the biopharmaceutical sector, is serving as Chief Executive Officer and as a member of the Boa...

리더십 팀

이름	위치	테뉴어	보상	소유권
Michael Metzger	CEO & Director	2.8yrs	US$9.13m	0.062% $ 844.0k
Neil Gallagher	President	1.6yrs	US$4.04m	0.015% $ 209.4k
Keith Goldan	CFO, Treasurer & Chief Accounting Officer	2.4yrs	US$2.83m	0.021% $ 281.1k
Luke Albrecht	Senior VP	8.3yrs	US$2.59m	0.051% $ 690.0k
Catherine Madigan	Chief Medical Officer	2.7yrs	US$2.81m	0.042% $ 576.3k
Peter Ordentlich	Co-Founder & Chief Scientific Officer	19.1yrs	데이터 없음	데이터 없음
Richard Heyman	Co-Founder	no data	데이터 없음	데이터 없음
Ronald Evans	Co-Founder	no data	데이터 없음	데이터 없음
Michael Downes	Co-Founder	no data	데이터 없음	데이터 없음
Sharon Klahre	Vice President of Investor Relations & Communications	2.4yrs	데이터 없음	데이터 없음
Kevin McManus	Chief People Officer	1.5yrs	데이터 없음	데이터 없음
Joseph Eder	Member of Scientific Advisory Board & Chief Medical Officer	1.9yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: SNDX 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Michael Metzger	CEO & Director	5.3yrs	US$9.13m	0.062% $ 844.0k
Ronald Evans	Co-Founder	8.3yrs	데이터 없음	데이터 없음
Joseph Eder	Member of Scientific Advisory Board & Chief Medical Officer	8.3yrs	데이터 없음	데이터 없음
Keith Katkin	Independent Director	7.7yrs	US$581.02k	0.037% $ 510.4k
Pierre Legault	Independent Director	7.8yrs	US$575.59k	0.037% $ 510.4k
Dennis Podlesak	Independent Chairman	15.9yrs	US$1.10m	0.017% $ 230.2k
George Sledge	Member of Scientific Advisory Board	7.6yrs	US$23.05k	데이터 없음
Jedd D. Wolchok	Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Hope Rugo	Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Samir Khleif	Member of Scientific Advisory Board	8.3yrs	데이터 없음	데이터 없음
Julie Brahmer	Member of Scientific Advisory Board	8.9yrs	데이터 없음	데이터 없음
Lisa Coussens	Member of Scientific Advisory Board	7.8yrs	데이터 없음	데이터 없음

8.3yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: SNDX 의 이사회는 경험(평균 재직 기간 8.3 년)으로 간주됩니다.

Syndax Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Syndax Pharmaceuticals, Inc. Announces Board Changes

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Director exercised options and sold US$715k worth of stock

Recent updates

Syndax Pharmaceuticals Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Syndax Pharmaceuticals, Inc. Announces Positive Pivotal Topline Results from Relapsed or Refractory Mnpm1 AML Cohort in Augment-101 Trial of Revumenib

Consensus revenue estimates increase by 197%

Syndax Pharmaceuticals, Inc. Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™? (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Consensus revenue estimates fall by 21%

Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia

Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index

Consensus revenue estimates increase by 12%

Syndax: Gearing Up For Launches

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

Syndax Pharmaceuticals, Inc. Announces Board Changes

Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Consensus EPS estimates fall by 23%

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.

Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program

Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Director notifies of intention to sell stock

Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Director notifies of intention to sell stock

Consensus revenue estimates decrease by 11%, EPS upgraded

Director exercised options and sold US$715k worth of stock

Director exercised options and sold US$794k worth of stock

Syndax Pharmaceuticals, Inc. Announces Executive Changes

President exercised options and sold US$695k worth of stock

President exercised options and sold US$853k worth of stock

Consensus EPS estimates fall by 21%

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Price target increased by 7.6% to US$34.44

Independent Director exercised options and sold US$616k worth of stock

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Co-Founder & Chief Scientific Officer exercised options and sold US$467k worth of stock

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Insufficient new directors

Consensus revenue estimates increase by 64%

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021)

Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias

Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

CEO & Director exercised options and sold US$549k worth of stock

President exercised options and sold US$4.4m worth of stock

Co-Founder & Chief Scientific Officer exercised options and sold US$468k worth of stock

Consensus forecasts updated

Independent Director exercised options and sold US$331k worth of stock

First half 2022 earnings released

Syndax Pharmaceuticals Q2 2022 Earnings Preview

Syndax Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insufficient new directors